Examples of 'decitabine' in a sentence
Meaning of "decitabine"
Decitabine is a medication used in the treatment of certain types of cancer, particularly acute myeloid leukemia
Show more definitions
- 5-aza-2'-deoxycytidine (trademark Dacogen), a cytosine analogue that hypomethylates DNA by inhibiting DNA methyltransferase.
How to use "decitabine" in a sentence
Basic
Advanced
decitabine
Two isomeric forms of decitabine can be distinguished.
This trial is to determine the toxicity of decitabine.
He wanted the decitabine and wanted me to go to the patient.
It contains the active substance decitabine.
No human data on the effect of decitabine on fertility are available.
Decitabine possesses multiple pharmacological characteristics.
Process for the synthesis of azacitidine and decitabine.
Decitabine is a nucleoside and a known pharmaceutically active compound.
Compositions comprising decitabine and tetrahydrouridine and uses thereof.
Decitabine is not a prohibited drug.
The active substance is decitabine.
The diluent and decitabine maybe contained in separate vessels.
Formal carcinogenicity studies have not been performed with decitabine.
It is not known whether decitabine or its metabolites are excreted in breast milk.
The corresponding scheme for the synthesis of decitabine is as follows.
See also
Decitabine is a hypomethylating agent.
No formal clinical drug interaction studies with decitabine have been conducted.
The diluent and the decitabine may be contained in separated vessels.
Preparation of decitabine.
Decitabine levels were assessed in µM.
Evidence from the literature indicates that decitabine has carcinogenic potential.
The decitabine may be dissolved in a solution of cyclodextrin compound at different concentrations.
Excretion of unchanged drug appears to play only a minor role in the elimination of decitabine.
Both azacitidine and decitabine are used in the treatment of myelodysplastic syndrome.
This maintaining a relative neutral pH may be advantageous for the formulation comprising the decitabine.
Decitabine and azacitidine are unstable in aqueous media and undergo hydrolytic degradation.
Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia.
Decitabine and azacitidine are unstable in aqueous media and undergo hydrolytic degradation in aqueous media.
Pharmacodynamics of decitabine alone and in combination with THU.
Decitabine blocks the action of a protein that modifies the DNA.
The DNA methyltransferase inhibitor is selected from azacitidine and decitabine.
Continuous exposure to decitabine may prevent cell division or even kill cells directly.
The mainstay of treatment for MDS patients are hypomethylating agents called azacitidine and decitabine.
These concentrations of decitabine did not cause DNA damage or immediate apoptosis.
The DNA methyltransferase inhibitor used in the dosing regimen of the present invention is decitabine.
Incorporation of decitabine into the DNA strand has a hypomethylation effect.
Wherein the CDA substrate drug is decitabine.
The PK of decitabine have not been formally studied in patients with hepatic impairment.
In one preferred embodiment, the decitabine is administered intravenously.
The PK of decitabine have not been formally studied in patients with renal insufficiency.
Through the request for experimental thalassemia medication, decitabine.
State of the Art Decitabine is a nucleoside and a known pharmaceutically active compound.
Neutropenia recovered within 7 days of the last decitabine dose.
Decitabine Vdss in cancer patients is large indicating distribution of the drug into peripheral tissues.
At higher doses, decitabine is known to be cytotoxic.
Decitabine is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA.
In cells, azacitidine can be converted to decitabine by the enzyme ribonucleotide reductase.
Decitabine is shown herein to deplete DNMTI without causing measurable DNA damage.
In still other embodiments, the second therapeutic agent is azacitidine or decitabine.
The combination of decitabine with THU has the potential to address both forms of relapse.
